CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new variants of the cerebral dopamine neurotrophic factor to treat Parkinson's disease by enabling them to cross the blood-brain barrier. The goal is to create peptides that can be delivered systemically, improving treatment options for both motor and non-motor symptoms.
Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by the progressive loss of midbrain dopamine neurons that leads to the severe movement disorders and several non-motor symptoms.
Available PD treatments do not provide long-lasting relief from the symptoms and do not slow down or stop the neurodegeneration.
Cerebral dopamine neurotrophic factor (CDNF) was shown to reverse the PD-associated neurodegeneration in vitro and in vivo in animal models.
Currently,…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
